CAU
ADPT icon

Caxton Associates (UK)’s Adaptive Biotechnologies ADPT Stock Holding History

Caxton Associates (UK)’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$500K Sell
36,035
-44,382
-55% -$707K 0.01% 502
2025
Q4 		$1.31M Buy
80,417
+3,218
+4% +$52.5K 0.03% 297
2025
Q3 		$1.15M Buy
+77,199
New +$941K 0.03% 310
2025
Q2 		– Sell
-12,475
Closed -$92.7K – 680
2025
Q1 		$92.7K Buy
+12,475
New +$95.9K ﹤0.01% 737

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caxton Associates (UK)'s ADPT Position: Q1 2026 in Review

Caxton Associates (UK) reduced its Adaptive Biotechnologies (ADPT) stake by 55% in Q1 2026, selling an estimated $707K and leaving 36,035 shares worth $500K. The position accounts for 0.01% of the portfolio, ranked #502.

Caxton Associates (UK) first reported a position in ADPT in Q1 2025 and has held it in 4 quarters since. The position peaked at $1.31M in Q4 2025. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Caxton Associates (UK) held 36,035 shares of Adaptive Biotechnologies worth $500K as of Q1 2026.
  • Caxton Associates (UK) sold 44,382 Adaptive Biotechnologies shares in Q1 2026, an estimated $707K.
  • Adaptive Biotechnologies made up 0.01% of Caxton Associates (UK)'s portfolio in Q1 2026, its #502 holding.
  • Caxton Associates (UK) first reported a position in Adaptive Biotechnologies in Q1 2025 and has held it in 4 quarters since.
  • Caxton Associates (UK)'s Adaptive Biotechnologies position peaked at $1.31M in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.